| Full Name | Kristin Armstrong |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Hand |
| Location | Psc 482, Fpo, Armed Forces Pacific |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740698273 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XH1200X | Occupational Therapist - Hand | KY-R5887 (Kentucky) | Primary |
| Provider Name | Proactive Physical Therapy & Sports Medicine Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1285729509 PECOS PAC ID: 1557369436 Enrollment ID: O20061201000533 |
News Archive
Cytori Therapeutics today received U.S. Patent No. 7,651,684 (the ‘684 patent) which covers the Company's methods for delivering adipose-derived stem and regenerative cell-enriched fat grafts into patients. The ‘684 patent specifically covers cell-enriched fat grafts to treat soft-tissue defects and urinary incontinence. In addition, the ‘684 patent covers methods for delivering cell-enriched fat grafts to a patient's breast, wrinkles, lips, under the eyes, cheeks, chin, and other parts of the body.
The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented in Atlanta, Georgia at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
The troubles with the health website took center stage on the Sunday news shows and in the Saturday weekly addresses from the president and the Republicans.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristin Armstrong, Psc 482, Fpo, AP 96362-9998 Ph: () - | Kristin Armstrong, Psc 482, Fpo, AP 96362-9998 Ph: (081) 646-7665 |
News Archive
Cytori Therapeutics today received U.S. Patent No. 7,651,684 (the ‘684 patent) which covers the Company's methods for delivering adipose-derived stem and regenerative cell-enriched fat grafts into patients. The ‘684 patent specifically covers cell-enriched fat grafts to treat soft-tissue defects and urinary incontinence. In addition, the ‘684 patent covers methods for delivering cell-enriched fat grafts to a patient's breast, wrinkles, lips, under the eyes, cheeks, chin, and other parts of the body.
The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented in Atlanta, Georgia at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
The troubles with the health website took center stage on the Sunday news shows and in the Saturday weekly addresses from the president and the Republicans.
› Verified 8 days ago
Jason Paul Jensen, OTR/L, CHT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc Bx 1, Fpo, AP 96350 Phone: 315-243-5348 | |
Sophia Maria Jurado, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 315-243-8649 | |
Mrs. Melody Capulong-schwartz, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc 482, Us Naval Hospital, Okinawa, Commanding Officer, Fpo, AP 96362 Phone: 011-816-117437555 | |
Ms. Brittany Anne Hutchison, M.S., OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 315-226-9039 | |
Mrs. Rowena Lontok Reyes, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc 475 Bx1, Fpo, AP 96350 Phone: 011-315-7260 | |
Angelique Nicole Barone, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc 475, Naval Hospital Yokosuka Japan, Fpo, AP 96350 Phone: 315-253-6495 | |
Ms. Maria Luz Barefield, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 315-243-8649 |